Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.125 -0.115 (-9.27%)
Streaming Delayed Price Updated: 12:11 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 Next >
Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy
October 7, 2025 – In a move that sent ripples across both the biotechnology and cryptocurrency sectors, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company... 
Via BreakingCrypto
Topics ETFs Economy
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
Via Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
--News Direct-- 
Via News Direct
Topics Death
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q4 2023
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer
--News Direct-- 
Via News Direct
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial results, issued guidance and declared an interim dividend. Wipro shares... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.